Literature DB >> 16923748

Serum anti-Mullerian hormone throughout the human menstrual cycle.

A La Marca1, G Stabile, A Carducci Artenisio, A Volpe.   

Abstract

BACKGROUND: The anti-Mullerian hormone (AMH) is a member of the transforming growth factor (TGF) superfamily. In women, AMH serum levels can be almost undetectable at birth, with a subtle increase noted after puberty. Data are lacking with regard to menstrual cycle day-to-day fluctuations. This longitudinal study was designed to investigate the pattern of secretion of AMH throughout the menstrual cycle in regularly cycling women.
METHODS: Twelve healthy female subjects aged 18-24 years participated in this study. Blood samples were taken every other day throughout one menstrual cycle. Serum FSH, LH, estradiol (E(2)), progesterone, inhibin B and AMH levels were assayed by double-antibody radioimmunoassay using commercial kits.
RESULTS: Serum AMH in the first days of the menstrual cycle (days -14 to -12) was 3.8 +/- 1.2 ng/ml (mean +/- SD). No significant changes were observed in serum AMH levels throughout the menstrual cycle. The highest value was 3.9 +/- 1.3 ng/ml at day -12 and the lowest value was 3.4 +/- 1.1 ng/ml at day 14, and the difference was not significant.
CONCLUSION: In this study, we demonstrated that serum AMH levels do not change significantly throughout the menstrual cycle. Hence, AMH exhibits a relatively stable expression during the menstrual cycle, making it an attractive determinant of ovarian activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923748     DOI: 10.1093/humrep/del291

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  109 in total

1.  Anti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundability.

Authors:  Donna D Baird; Anne Z Steiner
Journal:  Am J Epidemiol       Date:  2012-01-12       Impact factor: 4.897

2.  Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.

Authors:  Hiroyuki Honnma; Tsuyoshi Baba; Masahiro Sasaki; Yoshiki Hashiba; Hisanori Oguri; Takanori Fukunaga; Toshiaki Endo; Yoshimasa Asada
Journal:  J Assist Reprod Genet       Date:  2011-11-16       Impact factor: 3.412

3.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

Review 4.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

5.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

6.  68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study.

Authors:  Jie Zang; Feng Mao; Hao Wang; Jingjing Zhang; Qingxing Liu; Li Peng; Fang Li; Lixin Lang; Xiaoyuan Chen; Zhaohui Zhu
Journal:  Clin Nucl Med       Date:  2018-09       Impact factor: 7.794

7.  Anti-Müllerian hormone deficiency in females with Fanconi anemia.

Authors:  Martha M Sklavos; Neelam Giri; Pamela Stratton; Blanche P Alter; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-01-17       Impact factor: 5.958

8.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

9.  Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Authors:  MaryFran Sowers; Daniel McConnell; Katherine Gast; Huiyong Zheng; Bin Nan; Jenifer D McCarthy; John F Randolph
Journal:  Fertil Steril       Date:  2009-12-06       Impact factor: 7.329

10.  Serum antimüllerian hormone predicts ovarian reserve in a monkey model.

Authors:  Susan E Appt; Thomas B Clarkson; Haiying Chen; Michael R Adams; Patricia J Christian; Patricia B Hoyer; Mark E Wilson; Jay R Kaplan
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.